Table 4:
Multivariable logistic regression models of SIOP ≥2 hearing loss at end of therapy
| Model #1: Cisplatin daily dose | Model #2: Disease group | ||||||
|---|---|---|---|---|---|---|---|
| Covariable | event/ total (n/n) |
Odds Ratio (95% CI) |
p-value | Covariable | event/ total (n/n) |
Odds Ratio (95% CI) |
p-value |
| Age, years | Age, years | ||||||
| 0-5 | 7/17 | 1.03 (0.09, 12.36) | 0.055 | 0-5 | 7/17 | 5.02 (0.52, 48.67) | 0.106 |
| 6-10 | 6/11 | 12.52 (1.16, 134.89) | 6-10 | 6/11 | 14.25 (1.21, 167.92) | ||
| ≥11 | 2/14 | Reference group | ≥11 | 2/14 | Reference group | ||
| Cisplatin Daily Dose, mg/m2 | n/a | 1.05 (1.00, 1.10) | 0.033 | Tumor type | |||
| CNS | 8/15 | 0.89 (0.10, 7.70) | 0.309 | ||||
| OST | 3/10 | 0.74 (0.05, 11.27) | |||||
| Other | 1/9 | 0.08 (0.004, 1.70) | |||||
| Hepatic | 3/8 | Reference group | |||||
| NAC | NAC | ||||||
| Yes | 5/17 | 0.13 (0.02, 0.85) | 0.033 | Yes | 5/17 | 0.15 (0.02, 0.96) | 0.045 |
| No | 10/25 | Reference group | No | 10/25 | Reference group | ||
NAC = N-acetylcysteine; CNS = central nervous system tumor, OST = osteosarcoma.